Business Wire

Sky Labs Finalizes Series B Round Successfully Planning to Take Over Global Markets

Share

Attracting USD 20 million investment, Sky Labs (CEO: Jack Lee), a global health care start-up, finalized Series B Round successfully. The accumulated amount of investment Sky Labs has attracted is USD 30 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005004/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sky Labs, a global health care start-up, finalizes Series B Round successfully attracting USD 20 million investment. The accumulated amount of investment is USD 30 million. Sky Labs developed CART-I, the world’s first AI-based ring-type heart monitoring platform. It consists of a ring-type wearable medical device and user’s application and medical professional’s web platform and enables atrial fibrillation patients to conduct monitoring when they are not in a hospital. In addition, the photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger to measure irregular pulse waves. The measured data are transmitted to a cloud platform to have AI detect and analyze atrial fibrillation and the result is delivered to the user’s application and medical professional’s web. CART-I earned CE-MDD (Medical Devices Directive) and is being prepared for U.S FDA approval. (Photo: Business Wire)

In addition to returning investors such as Atinum Investment, Moru Asset Management and Soo Investment Capital, new investors such as KB Investment, Korea Investment Partners and LB Investment participated this time. It is noticeable that big investors managing more than KRW 1 trillion in Korea participated in the investment. Sky Labs explains that such a great achievement was possible because the technological competitiveness and business capacity of the company were highly recognized.

Sky Labs developed CART-I, the world’s first AI-based ring-type heart monitoring platform, which attracted attention in the healthcare market. CART-I consists of a ring-type wearable medical device and user’s application and medical professional’s web platform and enables atrial fibrillation patients to conduct monitoring when they are not in a hospital. In addition, the photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger to measure irregular pulse waves. The measured data are transmitted to a cloud platform to have AI detect and analyze atrial fibrillation and the result is delivered to the user’s application and medical professional’s web. CART-I earned CE-MDD (Medical Devices Directive) and is being prepared for U.S FDA approval.

Sky Labs has expanded its business in overseas markets since the beginning of this year. In January, CART-I was selected for clinical research to monitor atrial fibrillation led by professor Timothy Betts, a cardiologist at Oxford University Hospital. In April, Sky Labs signed a contract with Titan Commerce Continental Services GmbH, the largest wearable medical device distributor in Germany, to sell CART-I in Europe. It is ready for on/offline sales to hospitals and medical institutions in Germany, Austria and Switzerland.

Encouraged by the attracted investment, Sky Labs plans to expand global clinical research with the UK, the Netherlands, Germany and the U.S and strengthen the marketing activities of the U.S and European branches to take over global healthcare markets. In addition, it expects to develop monitoring devices for various chronic diseases, acquire approval for the devices and recruit manpower.

Kim Jinyong (M.D., Ph.D.), director of KB Investment which participated in Series B investment, said, “Analyzing heart rhythm precisely, conducting continuous monitoring of vital signs such as blood pressure and oxygen saturation and carrying out the medical analysis of the signs, CART-I is the most advanced wearable medical device. Continuous and precise monitoring outside a hospital for the constant care of chronic disease patients is an important element of tailor-made medical care. CART-I will realize it.”

Jack Lee, CEO of Sky Labs, said, “The investment we attracted this time verifies the technological and clinical capacity of our AI, software and hardware, the potential and expandability of CART platform and the high praise of our globally expanding business capacity. Accelerating the growth, we are going to bring fundamental changes to the healthcare market for chronic disease patients outside a hospital.”

Winning the Digital Health & Technology Competition of the European Society of Cardiology in 2018 and 2019 and selected as the Technology Pioneer of the World Economic Forum 2019, Sky Labs is highly recognized for its technology and competitiveness.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Sky Labs
Meet the sun
Shinhwa Park
+82.2.739.4931
sh.park@meetthesun.co.kr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Appoints Nicolas Mirzayantz President of IFF’s Nourish Division28.7.2021 23:00:00 EEST | Press release

IFF (NYSE: IFF) today announced that Nicolas Mirzayantz, current President, Scent, has been appointed President of IFF’s Nourish division, effective September 1, 2021. Mr. Mirzayantz will succeed Kathy Fortmann, current President, Nourish, who has decided to pursue other opportunities outside of IFF. IFF veteran and current President, Global Consumer Fragrances, Christophe de Villeplee, will assume transition into the role of President, Scent. “We could not be more pleased to have Nicolas lead our Nourish division,” said IFF Chairman and CEO, Andreas Fibig. “Nicolas is joining a Nourish division with a tremendous opportunity to build on significant sales momentum and strong customer interest in IFF’s differentiated portfolio and capabilities. He has been an invaluable member of our leadership team, with an unparalleled ability to create a culture of innovation and deliver creative and winning solutions to our customers while consistently strengthening the business through growth and ma

Stilla Launches Access Program for Industry’s First Six-Color Digital PCR System28.7.2021 19:26:00 EEST | Press release

Stilla Technologies, the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industry’s first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today. This represents a broad portfolio expansion of the Company’s original three-color naica® system and includes reagents and digital PCR consumables, automated analytical instrumentation, and turnkey visualization software. The commercial launch of the six-color naica® system is scheduled for Fall 2021. “There is undeniable value in detecting and quantifying multiple mutations, viruses and biomarkers from a single sample. The cost versus depth tradeoffs of NGS make it impractical for the routine testing of many samples per day, while multiplex qPCR lacks the precise quantitation a

Q4 Helps Public Companies and Investment Firms Keep Their Teams Aligned and Informed28.7.2021 16:00:00 EEST | Press release

Q4 Inc. announced today it is applying its unique expertise in delivering mission-critical virtual events to help public companies, buy-side and sell-side firms build transparency, trust and excitement across a widely dispersed workforce. With the seismic shift in working models giving employees increasing flexibility to work both in remote or hybrid setups, maintaining a strong internal communications platform to globally distributed teams is vital for companies across all industries. Simultaneously, the commitment to providing a sustainable work environment and strong corporate culture continues to intensify as companies seek to implement successful ESG policies and programs. Q4’s new Corporate Town Hall subscriptions combine technology and a premium end-to-end service model to help its capital markets clients communicate strategy and best practices, provide quarterly business reviews, host sales kick-offs, and ultimately foster the inclusive culture they have worked so hard to devel

ZS Elects Pratap Khedkar to CEO28.7.2021 16:00:00 EEST | Press release

Global professional services firm ZS today announced that Pratap Khedkar, head of the firm’s global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firm’s leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005232/en/ Pratap Khedkar, CEO, ZS (Photo: Business Wire) Khedkar is the third CEO in ZS’s nearly 40-year history. He was elected by his peers, a structure ZS’s founders Andris A. Zoltners and Prabhakant Sinha established to ensure cultural continuity and to elevate leaders who embody the company’s dedication to strategy, innovation and client collaboration. He succeeds Chris Wright, who served the firm’s maximum term and will be affiliated with ZS for the next five years as part of its principal emeritus program, focusing on the projects that he’s most passionate about. Khedkar has held various leadership roles during his 21 years with ZS. Khedkar has led the firm’s global

Dixa, the Next-Gen CX Platform, Raises $105M Series C to Transform Customer Service Worldwide28.7.2021 15:30:00 EEST | Press release

Founded as a customer service solution that evolved into a customer engagement platform, European company Dixa today announced a Series C funding round totaling $105M. The company is leading the change from customer service to value creation with a multiexperience approach, challenging the status quo and delivering value-driven experiences that generate results for businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005430/en/ Dixa Founding Team (Photo: Business Wire) The Series C round is led by General Atlantic, a leading global growth equity investor with a history of backing and scaling companies that transformed their industries, with participation from existing investors Notion Capital Project A and Seed Capital. Dixa will leverage the new funds to invest in product development, including potential new acquisitions (following Dixa’s acquisition of Melbourne-based Elevio in January 2021), and plans to quadr

V.E, Part of Moody’s ESG Solutions, Provides Second Party Opinion on the Kingdom of Spain’s Sovereign Green Bond Framework28.7.2021 15:30:00 EEST | Press release

Moody’s ESG Solutions Group announced today that V.E has provided a Second Party Opinion (SPO) on the Kingdom of Spain’s Sovereign Green Bond Framework. The Framework is aligned with the four core components of the Green Bond Principles 2021 and follows best market practices identified by V.E. Net proceeds of the bonds will exclusively be used to finance or refinance projects tied to the country’s environmental objectives, including renewable energy, biodiversity protection, and climate change adaptation. “The bonds issued under Spain’s Framework will provide an ‘advanced’ contribution to sustainability, the highest score on our four-point scale,” said Patrick Mispagel, MD – Sustainable Finance at Moody’s ESG Solutions. “Our assessment reflects that in many cases Spain’s Framework followed the detailed technical eligibility criteria of the EU Taxonomy Climate Delegated Act. We expect to see additional sovereign issuances as nations increasingly seek to raise capital to support climate

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)28.7.2021 15:15:00 EEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. TAK-994 is currently being studied for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1),2 a chronic neurological disorder that alters the sleep-wake cycle.3 EDS is a hallmark symptom of NT1 and is characterized by a person’s inability to stay awake and alert throughout the day, and falling asleep unintentionally or at inappropriate times on a daily basis.3,4 The FDA’s Breakthrough Therapy Designation process is designed to expedite the development and review of a drug that is intended to treat a serious condition, for which preliminary clinical evidence exists indicating it may demonstrate a substantial improvement over available therapies on at

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom